Effect of dose A
DISEASE PROGRESSION
Throughout the disease progression, in group A, most of the interleukins (IL-4, IL-2, IL-1β, IL-6, IL-8, IL-12, IL-10, IL-17A, TNF-α, and TGF-β1) remained unchanged, as indicated by Modulation of relative IL-4, IL-12, TGF-β1, and IL-10 cytokines levels over time.Relative amounts were calculated as a percentage of the baseline value on day 0. Mean ± standard error values are reported for each interleukin. Statistically significant differences compared to the control group are indicated by an asterisk (*) when p ≤ 0.05.Antibody level progression. Mean ± standard error values are reported. Statistically significant differences compared to control are indicated by * (group A) when p ≤ 0.05.